1. Repurposing lansoprazole to alleviate metabolic syndrome via PHOSPHO1 inhibition
- Author
-
Yingting Wu, Jiaqi Xin, Xinyu Li, Ting Yang, Yi Liu, Yongsheng Zhao, Wen Xie, and Mengxi Jiang
- Subjects
Lansoprazole ,Proton pump inhibitors ,Adipose thermogenesis ,Energy expenditure ,Metabolic syndrome ,PHOSPHO1 inhibitor ,Therapeutics. Pharmacology ,RM1-950 - Abstract
Drug repurposing offers an efficient approach to therapeutic development. In this study, our bioinformatic analysis first predicted an association between obesity and lansoprazole (LPZ), a commonly prescribed drug for gastrointestinal ulcers. We went on to show that LPZ treatment increased energy expenditure and alleviated the high-fat diet-induced obesity, insulin resistance, and hepatic steatosis in mice. Treatment with LPZ elicited thermogenic gene expression and mitochondrial respiration in primary adipocytes, and induced cold tolerance in cold-exposed mice, suggesting the activity of LPZ in promoting adipose thermogenesis and energy metabolism. Mechanistically, LPZ is an efficient inhibitor of adipose phosphocholine phosphatase 1 (PHOSPHO1) and produces metabolic benefits in a PHOSPHO1-dependent manner. Our results suggested that LPZ may stimulate adipose thermogenesis by inhibiting the conversion of 2-arachidonoylglycerol-lysophosphatidic acid (2-AG-LPA) to 2-arachidonoylglycerol (2-AG) and reduce the activity of the thermogenic-suppressive cannabinoid receptor signaling. In summary, we have uncovered a novel therapeutic indication and mechanism of LPZ in managing obesity and its related metabolic syndrome, and identified a potential metabolic basis by which LPZ improves energy metabolism.
- Published
- 2024
- Full Text
- View/download PDF